TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement.

FAS-UP was subset of subjects in safety evaluation set (SES-UP) for whom at least one score of tremor amplitude at wrist level (injected UL) at study baseline and at least at one post-baseline score was available. "Overall number of participants analyzed" signifies subjects evaluable for this outcome measure. The analysis was performed by randomized treatment (one subject randomized to NT 201 was erroneously treated with placebo and one subject randomized to placebo was not treated).

The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

Full analysis set for unilateral treatment period (FAS-UP) was subset of subjects in SES-UP for whom at least one score of tremor amplitude at wrist level (injected UL) at study baseline and at least at one post-baseline score was available. The analysis was performed by randomized treatment (one subject randomized to NT 201 was erroneously treated with placebo and one subject randomized to placebo was not treated).

TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor [items 2-9]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

FAS-UP was subset of subjects in SES-UP for whom at least one score of tremor amplitude at wrist level (injected UL) at study baseline and at least at one post-baseline score was available. The analysis was performed by randomized treatment (one subject randomized to NT 201 was erroneously treated with placebo and one subject randomized to placebo was not treated).

TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

FAS-UP was subset of subjects in SES-UP for whom at least one score of tremor amplitude at wrist level (injected UL) at study baseline and at least at one post-baseline score was available. The analysis was performed by randomized treatment (one subject randomized to NT 201 was erroneously treated with placebo and one subject randomized to placebo was not treated).

The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

FAS-UP was subset of subjects in SES-UP for whom at least one score of tremor amplitude at wrist level (injected UL) at study baseline and at least at one post-baseline score was available. The analysis was performed by randomized treatment (one subject randomized to NT 201 was erroneously treated with placebo and one subject randomized to placebo was not treated).

The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

FAS-UP was subset of subjects in SES-UP for whom at least one score of tremor amplitude at wrist level (injected UL) at study baseline and at least at one post-baseline score was available. The analysis was performed by randomized treatment (one subject randomized to NT 201 was erroneously treated with placebo and one subject randomized to placebo was not treated).

TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

The full analysis set for the bilateral treatment period (FAS-BP) was the subset of subjects in the safety evaluation set for the bilateral treatment period (SES-BP that is, all subjects who received NT 201 during the bilateral treatment period) for whom at least one score of tremor amplitude at wrist level at the Cycle 2 baseline visit and at least at one post-baseline score.

The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity.

The FAS-BP was the subset of subjects in the SES-BP (that is, all subjects who received NT 201 during the bilateral treatment period) for whom at least one score of tremor amplitude at wrist level at the Cycle 2 baseline visit and at least at one post-baseline score.

TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

The FAS-BP was the subset of subjects in the SES-BP (that is, all subjects who received NT 201 during the bilateral treatment period) for whom at least one score of tremor amplitude at wrist level at the Cycle 2 baseline visit and at least at one post-baseline score.

TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

The FAS-BP was the subset of subjects in the SES-BP (that is, all subjects who received NT 201 during the bilateral treatment period) for whom at least one score of tremor amplitude at wrist level at the Cycle 2 baseline visit and at least at one post-baseline score.

An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36).

The safety evaluation set for unilateral treatment period (SES-UP) included all subjects who received NT 201 or placebo during the unilateral treatment period and SES-BP included all subjects who received NT 201 during the bilateral treatment period. For the unilateral treatment period, the analysis performed according to actual treatment (one subject was treated with placebo even so randomized to NT 201 and one subject was not treated even so randomized to placebo).